MC
ELOS

Moors & Cabot’s Syneron Medical Ltd ELOS Stock Holding History

Moors & Cabot’s Portfolio ELOS Stock Details ELOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-57,524
Closed -$612K – 561
2017
Q1 		$612K Buy
57,524
+250
+0.4% +$2.42K 0.1% 237
2016
Q4 		$477K Buy
57,274
+1,250
+2% +$9.8K 0.08% 294
2016
Q3 		$401K Hold
56,024
– – 0.07% 314
2016
Q2 		$434K Sell
56,024
-1
-0% -$7 0.08% 283
2016
Q1 		$408K Sell
56,025
-2,100
-4% -$15K 0.07% 285
2015
Q4 		$453K Sell
58,125
-3,100
-5% -$23.6K 0.08% 271
2015
Q3 		$437K Buy
61,225
+800
+1% +$7.69K 0.08% 280
2015
Q2 		$644K Sell
60,425
-1,300
-2% -$15.2K 0.1% 240
2015
Q1 		$756K Buy
61,725
+16,924
+38% +$187K 0.13% 191
2014
Q4 		$416K Sell
44,801
-1,000
-2% -$9.64K 0.07% 302
2014
Q3 		$460K Buy
45,801
+1,250
+3% +$12.7K 0.08% 274
2014
Q2 		$456K Sell
44,551
-1,000
-2% -$10.8K 0.08% 284
2014
Q1 		$567K Buy
+45,551
New +$540K 0.14% 166

Other funds holding ELOS

BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
GLAM
Gardner Lewis Asset Management Chadds Ford, Pennsylvania $462M AUM 65.29% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
DGHMC
Dalton, Greiner, Hartman, Maher & Co New York $126M AUM 92.88% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Moors & Cabot's ELOS Position: Q2 2017 in Review

Moors & Cabot sold out of Syneron Medical Ltd (ELOS) in Q2 2017, closing a stake of 57,524 shares — an estimated $612K sold.

Moors & Cabot first reported a position in ELOS in Q1 2014 and held it in 13 quarters. The position peaked at $756K in Q1 2015. 79 funds tracked by Wall St. Rank hold ELOS as of Q2 2017.

  • Moors & Cabot reported no remaining Syneron Medical Ltd position as of Q2 2017 after selling out during the quarter.
  • Moors & Cabot sold 57,524 Syneron Medical Ltd shares in Q2 2017, an estimated $612K.
  • Moors & Cabot first reported a position in Syneron Medical Ltd in Q1 2014 and held it in 13 quarters.
  • Moors & Cabot's Syneron Medical Ltd position peaked at $756K in Q1 2015.
  • 79 funds tracked by Wall St. Rank held Syneron Medical Ltd as of Q2 2017.

Based on Moors & Cabot's 13F filing for Q2 2017, filed 15 Aug 2017.